Vedolizumab levels during induction are associated with long-term clinical and endoscopic remission in patients with inflammatory bowel disease

被引：0
|
作者：
Yarur, A. [1 ]
Bruss, A. [1 ]
Fox, C. [1 ]
Beniwal-Patel, P. [1 ]
Patel, A. [1 ]
Berens, B. [1 ]
Naik, S. [2 ]
Stein, D. [1 ]
机构：
[1] Med Coll Wisconsin, Gastroenterol & Hepatol, Milwaukee, WI 53226 USA
[2] Prometheus Labs, San Diego, CA USA
来源：
JOURNAL OF CROHNS & COLITIS | 2018年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP048
引用
收藏
页码：S64 / S65
页数：2
相关论文
共 50 条
  • [21] Vedolizumab Immunogenicity With Long-Term or Interrupted Treatment of Patients With Inflammatory Bowel Disease
    Wyant, Timothy
    Yang, Lili
    Lirio, Richard A.
    Rosario, Maria
    JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 61 (09): : 1174 - 1181
  • [22] Pseudopolyps are associated with increased fecal calprotectin levels in patients with Inflammatory Bowel Disease in clinical and endoscopic remission
    Spigarelli De Rabago, I.
    Suarez Ferrer, C.
    Poza Cordon, J.
    Martin Arranz, E.
    Sanchez Azofra, M.
    Rueda Garcia, J. L.
    Suarez Cabredo, C. G.
    Hernandez Perez, M.
    Martin Arranz, M. D.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S270 - S271
  • [23] Long-Term Efficacy of Vedolizumab in Pediatric Inflammatory Bowel Disease
    Sarles, Harry E., Jr.
    Whitney, Annette E.
    Kuten, Samantha A.
    Van Anglen, Lucinda J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S643 - S644
  • [24] Effectiveness and safety of vedolizumab for the induction of remission in inflammatory bowel disease
    Chaparro, M.
    Sierra-Ausin, M.
    Mesonero, F.
    Maroto, N.
    Fernandez de Castro, C.
    Garcia-Sanchez, V.
    Lucendo, A. J.
    Busquets, D.
    Barreiro-de Acosta, M.
    Marin-Jimenez, I.
    Beltran, B.
    Ruiz Belmonte, L.
    Bermejo, F.
    Minguez, M.
    Pajares, R.
    Pineda, J. R.
    Sicilia, B.
    Martin-Rodriguez, D.
    Gutierrez, A.
    Rubio, S.
    Garcia Tercero, I.
    Piqueras, M.
    Ginard, D.
    Jucha, B.
    Munoz Villafranca, C.
    Martin-Arranz, M. D.
    Marti Romero, L.
    Fernandez Bonilla, E. M.
    Echarri, A.
    Forcelledo, J. F.
    Donday, M. G.
    Ramas, M.
    Gisbert, J. P.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S416 - S417
  • [25] HIGHER VEDOLIZUMAB TROUGH LEVELS ASSOCIATED WITH REMISSION IN INFLAMMATORY BOWEL DISEASE (IBD) DURING MAINTENANCE THERAPY
    Ungaro, Ryan C.
    Jossen, Jacqueline
    Phan, Becky L.
    Chefitz, Ezra
    Sehgal, Priya
    Jain, Anjali
    Naik, Snehal
    Dubinsky, Marla
    GASTROENTEROLOGY, 2017, 152 (05) : S384 - S385
  • [26] vedolizumab trough levels at week 6 and 14 correlate with clinical remission in inflammatory bowel disease patients
    Marino, M.
    Domenis, R.
    Biribin, L.
    Cifu, A.
    Navarria, L.
    Scardino, G.
    Fabris, M.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S492 - S492
  • [27] Clinical outcomes of vedolizumab withdrawal in inflammatory bowel disease for patients in histological remission
    Blad, William
    Whitley, Lisa
    Harrow, Paul
    GUT, 2023, 72 (SUPPL_2) : A87 - A88
  • [28] Infliximab trough levels for remission induction and long term therapy management of inflammatory bowel disease
    Perdigoto, D.
    Portela, F.
    Ferreira, M.
    Mendes, S.
    Freire, P.
    Ferreira, M.
    Lopes, S.
    Tome, L.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S386 - S386
  • [29] An update on the safety of long-term vedolizumab use in inflammatory bowel disease
    Honap, Sailish
    Netter, Patrick
    Danese, Silvio
    Peyrin-Biroulet, Laurent
    EXPERT OPINION ON DRUG SAFETY, 2023,
  • [30] Combination therapy is not associated with improved rates of clinical or endoscopic remission in patients with inflammatory bowel disease treated with ustekinumab or vedolizumab: a retrospective study
    Jeffrey, Angus W.
    Picardo, Sherman
    Menon, Shankar
    So, Kenji
    Venugopal, Kannan
    ANNALS OF GASTROENTEROLOGY, 2023, 36 (04): : 430 - 436
12345